Author: admin

E. Jason Abel, M.D. of the University of Wisconsin presents “Patient Selection for Surgery in RCC with Thrombus” at the 14th International Kidney Cancer Symposium.

Dipen J. Parekh, MD of the University of Miami Miller School of Medicine presents “WARMING UP TO ISCHEMIA” at the 14th International Kidney Cancer Symposium

Karim Touijer , MD, MPH from the Memorial Sloan-Kettering Cancer Center presents “Partial Nephrectomy: Does Ischemia Matter?” at the 14th International Kidney Cancer Symposium

James Porter of the Swedish Medical Center Seattle, WA presents “Minimally Invasive Lymphadenectomy for Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Steven C. Campbell, MD, PhD of The Cleveland Clinic discusses “Optimal Treatment of cT1b Renal Mass in Patient with Normal GFR: a Role for Radical Nephrectomy?” at the 14th International Kidney Cancer Symposium.

Michael A. Gorin, M.D. of Johns Hopkins University School of Medicine discusses “Novel Imaging Techniques in RCC” at the 14th International Kidney Cancer Symposium.

Michael Bassetti MD PhD of the University of Wisconsin Madison discusses “University of Wisconsin Madison” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

R. Houston Thompson, MD Professor of Urology Mayo Clinic discusses “Partial Nephrectomy or Ablation for Small Renal Mass” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Michael A.S. Jewett discusses “Surveillance is the Best Treatment for T1a RCC in a healthy 65 year old patient” at the Fourteenth International Kidney Cancer Symposium Miami, Florida, USA, November 6th , 2015 www.kidneycancersymposium.com

Stephen A. Boorjian, MD of the Mayo Clinic, Rochester, MN discusses ” CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Bradley C. Leibovich, MD, FACS , Mayo Clinic debates ” Renal Mass Biopsy Should Be Used Sparingly in patients with SRM” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Tony Finelli, MD, MSc, FRCSC Head, Division of Urology GU Site Lead, Princess Margaret Cancer Center debates the Pro side to “Renal Mass Biopsy Should be Used for Most SRM – PRO” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

A Ari Hakimi MD Memorial Sloan Kettering Cancer Center brings an “Update on Molecular and Genetic Characterization of RCC” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Brian R. Lane, M.D., Associate Professor, Michigan State University discusses “Improving Healthcare Delivery in Kidney Cancer” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Dorothy Yang gives an overview of a study assessing the physical activity levels and barriers to exercise referral among patients with cancer, at the Bedford Hospital, Bedford, UK. The results of this study were presented at at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.

James Larkin, MD, PhD gives an update on the clinical trial CheckMate 067, a phase 3 study of Nivolumab or Nivolumab plus Ipilimumab versus Ipilimumab alone in previously untreated advanced melanoma. This updated was presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.       update, update checkmate 067, phase 3 study, nivolumab, nivolumab plus ipilimumab, ipilimumab alone, in previously untreated advanced melanoma, advanced melanoma, ncri 2015, ncri, national cancer research institute, cancer conference

Robert Thomas, MbChb, MRCP, MD, FRCR, gives an overview of the session “Physical activity the panacea?” at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.

Prof. Rob Coleman gives an overview of the session “This house believes we should stop focussing on the causes of breast cancer and get on with strategies to prevent the disease”, presented at the 2015 NCRI Cancer Conference. With Douglas Easton and Tim Key supporting the causes side, and Annie Anderson and Gareth Evans supporting the prevention side. The session was hosted by Prof. Rob Coleman.

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, discusses topics covered by scientists from the Francis Crick Institute at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. These include Tim Hunt, Richard Treisman, Nicholas Luscombe, Erik Sahai and Adrian Hayday. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the featured sessions of the 2015 National Cancer Research Institute (NCRI) Cancer Conference. These include sessions by Alberto Bardelli, Thierry Voet, Erik Sahai, Adrian Hayday, James Larkin, Sergio Quezada, Robert Peston and Fabrice André. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the 2015 National Cancer Research Institute (NCRI) Cancer Conference, which will focus on integrating basic, translational and clinical cancer research, and cover topics such as cancer evolution, single cell genomics, cancer immunology, cancer cell cycle and health economics in cancer. Key speakers and hosts include Thierry Voet, Alberto Bardelli, Adrian Hayday, Sergio Quezada, Tim Hunt, Denis Slamon and Robert Peston. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Previously, risk reduction from treatment with endocrine therapy has been represented as a general percentage for all patients treated. Knowing that in reality each patient responds differently, Dr. Naughton stresses the importance of tailoring treatment decisions based on the individual patient situation. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses Trial Assigning IndividuaLized Options for Treatment (TAILORx), a prospective phase 3 clinical trial that was designed to evaluate the utility of the Oncotype DX® Breast Cancer Assay to risk stratify patients with oestrogen receptor-positive, HER2-negative, node-negative breast cancer. By identifying low-risk patients who are unlikely to benefit from adjuvant chemotherapy, the test may allow physicians to direct patients to individualised therapies that are associated with improved health outcomes. This content is supported by Genomic Health, Inc. European Medical Journal…

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses an open-label, biomarker-directed, multi-drug, multi-centre, multi-arm, randomised phase 1b clinical trial in patients with muscle-invasive urothelial carcinoma of the bladder who have progressed on prior treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Naughton discusses the bothersome side effects and serious safety risks associated with endocrine therapy. He emphasizes the need to weigh patient benefit versus the impact on quality of life due to these side effects and safety risks when considering patient treatment options. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, outlines potential therapeutic applications, including immune and adaptive approaches, of an improved understanding of cancer genes and mutational processes. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses Patient Reported Opinions about Clinical Tolerability (PROACT), a mobile platform designed to enable patients to directly contribute to the understanding of investigational agents in early clinical development. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK, discusses a European Registration of Cancer Care (EURECCA) international comparison of treatment patterns for patients aged 70 years and older with non-metastatic breast cancer in four European countries. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. Nancy Zhu – Case-Based Discussion for Managing MDS Patients. This live webinar took place on September 10, 2015.

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, explains that anti-tumour immunity has the potential to be exploited clinically against the evolutionary process that drives cancer development. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses the results from the European Thoracic Oncology Platform (ETOP) Lungscape Project, a study of the molecular epidemiology of resected stage I-III non-small cell lung cancer (NSCLC) tumours and association with clinicopathological features and outcomes in patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, reviews the emerging understanding of mutational drivers of tumour heterogeneity, including APOBEC-mediated mutagenesis, that could support the development of future therapeutic strategies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. Martin Reck – ECC 2015 Immunotherapy Updates

@OncEd Presents Dr Luis Bruno – ECC 2015 GU Cancer Highlights (Portuguese Version)

@OncEd Presents Dr. Stephanie Snow – ECC 2015 Head and Neck Updates

@OncEd Presents Dr. Scott Berry – ICECREAM Trial

@OncED Presents Dr. Scott Berry – COMET Trial

@OncEd Presents Dr. Nadia Harbeck – PALOMA 3 Trial

@OncEd Presents Dr. Ralph Wong – Neuroendocrine Tumour Updates

@OncEd Presents Dr. Ramon Andrade de Mello – Hypermethylation of the TERT Promoter (Portuguese Version)

@OncEd Presents Dr. Ramon Andrade de Mello – Hypermethylation of the TERT Promoter

@OncEd Presents Dr. Silke Gillessen – SAKK 08/11 Study

@OncEd Presents Dr. Vladimir Milovanov – Predicting incomplete cytoreduction and aborted HIPEC in PC

@OncEd Presents Dr. Juan Pablo Marquez Manriquez – Multi-Antigen Vaccination for Colon Cancer Treatment and Prevention

@OncEd Presents Dr. Sunil Verma – ECC 2015 Breast Cancer Updates

@OncEd Presents Dr. Jeff Weber – Novel Combinations with Checkpoint Inhibitors

@OncEd Presents Dr. Stephen Doral Stefani – Access and Equity

@OncEd Presents Dr. Wolfgang Janni – DETECT Study

@OncEd Presents Dr. Jean Fayette – UNICANCER Trial

@OncEd Presents Dr Michael Untch – GEPARQUINTO Study